Received Apr 20, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | 944941 | — |
First Dose of Heplisav-B on 2024-Sep-14, Has Not Had the Second Dose Yet; Initial report received on 30-Mar-2026. A pharmacist reported that a patient (age and gender not provided) received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and has not received the second dose yet. No medical history or concomitant medications were reported. On 14-Sep-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number 944941; expiration date, NDC number, route, and site not available)]. On 30-Mar-2026, 562 days after receiving the first dose of HEPLISAV-B, the patient has not had the second dose yet. The patient denied any side effects. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.